EP Wealth Advisors LLC Invests $273,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

EP Wealth Advisors LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,384 shares of the medical research company’s stock, valued at approximately $273,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC raised its stake in shares of Charles River Laboratories International by 33.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,114 shares of the medical research company’s stock worth $1,263,000 after buying an additional 1,535 shares during the last quarter. Envestnet Portfolio Solutions Inc. raised its position in Charles River Laboratories International by 0.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 9,706 shares of the medical research company’s stock worth $2,005,000 after acquiring an additional 75 shares during the last quarter. Fiduciary Financial Group LLC purchased a new stake in shares of Charles River Laboratories International in the second quarter valued at about $258,000. Blue Trust Inc. grew its position in shares of Charles River Laboratories International by 19.1% in the second quarter. Blue Trust Inc. now owns 1,459 shares of the medical research company’s stock valued at $301,000 after purchasing an additional 234 shares during the last quarter. Finally, Boston Trust Walden Corp increased its stake in shares of Charles River Laboratories International by 2.8% during the 2nd quarter. Boston Trust Walden Corp now owns 200,314 shares of the medical research company’s stock worth $41,381,000 after purchasing an additional 5,375 shares in the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Robert W. Baird reduced their target price on Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, September 20th. Evercore ISI upped their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. UBS Group increased their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Redburn Atlantic started coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. Finally, StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and an average price target of $214.00.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $190.45 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $176.48 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The firm has a 50 day moving average price of $194.35 and a 200 day moving average price of $203.10. The company has a market cap of $9.74 billion, a price-to-earnings ratio of 23.84, a PEG ratio of 5.00 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.72 EPS. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 1.30% of the stock is currently owned by insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).